Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market 2022 by Company, Regions, Type and Application, Forecast to 2028

  • receipt Report ID : 99835
  • calendar_today Published On: Mar, 2022
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Tumor Necrosis Factor (TNF) Inhibitor Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global Tumor Necrosis Factor (TNF) Inhibitor Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Rheumatoid Arthritis accounting for % of the Tumor Necrosis Factor (TNF) Inhibitor Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Humira segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Tumor Necrosis Factor (TNF) Inhibitor Drugs include AbbVie Inc., Amgen Inc., Johnson & Johnson Services, Inc., UCB S.A., and Novartis International AG, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Tumor Necrosis Factor (TNF) Inhibitor Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Humira

Enbrel

Remicade

Simponi/Simponi Aria

Cimzia

Biosimilars

Market segment by Application, can be divided into

Rheumatoid Arthritis

Psoriasis

Psoriatic Arthritis

Crohn’s Disease

Ulcerative Colitis

Ankylosing Spondylitis

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa

Others

Market segment by players, this report covers

AbbVie Inc.

Amgen Inc.

Johnson & Johnson Services, Inc.

UCB S.A.

Novartis International AG

Pfizer, Inc.

Merck & co., Inc.

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Tumor Necrosis Factor (TNF) Inhibitor Drugs product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Tumor Necrosis Factor (TNF) Inhibitor Drugs, with revenue, gross margin and global market share of Tumor Necrosis Factor (TNF) Inhibitor Drugs from 2019 to 2022.

Chapter 3, the Tumor Necrosis Factor (TNF) Inhibitor Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Tumor Necrosis Factor (TNF) Inhibitor Drugs market forecast, by regions, type and application, with revenue, from 2023 to 2028.

Chapter 11 and 12, to describe Tumor Necrosis Factor (TNF) Inhibitor Drugs research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1 Market Overview

1.1 Product Overview and Scope of Tumor Necrosis Factor (TNF) Inhibitor Drugs

1.2 Classification of Tumor Necrosis Factor (TNF) Inhibitor Drugs by Type

1.2.1 Overview: Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Type in 2021

1.2.3 Humira

1.2.4 Enbrel

1.2.5 Remicade

1.2.6 Simponi/Simponi Aria

1.2.7 Cimzia

1.2.8 Biosimilars

1.3 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market by Application

1.3.1 Overview: Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Rheumatoid Arthritis

1.3.3 Psoriasis

1.3.4 Psoriatic Arthritis

1.3.5 Crohn’s Disease

1.3.6 Ulcerative Colitis

1.3.7 Ankylosing Spondylitis

1.3.8 Juvenile Idiopathic Arthritis

1.3.9 Hidradenitis Suppurativa

1.3.10 Others

1.4 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size & Forecast

1.5 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Forecast by Region

1.5.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Region, (2017-2022)

1.5.3 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Prospect (2017-2028)

1.5.4 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Prospect (2017-2028)

1.5.6 South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Drivers

1.6.2 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Restraints

1.6.3 Tumor Necrosis Factor (TNF) Inhibitor Drugs Trends Analysis

2 Company Profiles

2 Company Profiles

2.1 AbbVie Inc.

2.1.1 AbbVie Inc. Details

2.1.2 AbbVie Inc. Major Business

2.1.3 AbbVie Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product and Solutions

2.1.4 AbbVie Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 AbbVie Inc. Recent Developments and Future Plans

2.2 Amgen Inc.

2.2.1 Amgen Inc. Details

2.2.2 Amgen Inc. Major Business

2.2.3 Amgen Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product and Solutions

2.2.4 Amgen Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Amgen Inc. Recent Developments and Future Plans

2.3 Johnson & Johnson Services, Inc.

2.3.1 Johnson & Johnson Services, Inc. Details

2.3.2 Johnson & Johnson Services, Inc. Major Business

2.3.3 Johnson & Johnson Services, Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product and Solutions

2.3.4 Johnson & Johnson Services, Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Johnson & Johnson Services, Inc. Recent Developments and Future Plans

2.4 UCB S.A.

2.4.1 UCB S.A. Details

2.4.2 UCB S.A. Major Business

2.4.3 UCB S.A. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product and Solutions

2.4.4 UCB S.A. Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 UCB S.A. Recent Developments and Future Plans

2.5 Novartis International AG

2.5.1 Novartis International AG Details

2.5.2 Novartis International AG Major Business

2.5.3 Novartis International AG Tumor Necrosis Factor (TNF) Inhibitor Drugs Product and Solutions

2.5.4 Novartis International AG Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Novartis International AG Recent Developments and Future Plans

2.6 Pfizer, Inc.

2.6.1 Pfizer, Inc. Details

2.6.2 Pfizer, Inc. Major Business

2.6.3 Pfizer, Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product and Solutions

2.6.4 Pfizer, Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 Pfizer, Inc. Recent Developments and Future Plans

2.7 Merck & co., Inc.

2.7.1 Merck & co., Inc. Details

2.7.2 Merck & co., Inc. Major Business

2.7.3 Merck & co., Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product and Solutions

2.7.4 Merck & co., Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 Merck & co., Inc. Recent Developments and Future Plans

3 Market Competition, by Players

3 Market Competition, by Players

3.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Tumor Necrosis Factor (TNF) Inhibitor Drugs Players Market Share in 2021

3.2.2 Top 10 Tumor Necrosis Factor (TNF) Inhibitor Drugs Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Tumor Necrosis Factor (TNF) Inhibitor Drugs Players Head Office, Products and Services Provided

3.4 Tumor Necrosis Factor (TNF) Inhibitor Drugs Mergers & Acquisitions

3.5 Tumor Necrosis Factor (TNF) Inhibitor Drugs New Entrants and Expansion Plans

4 Market Size Segment by Type

4 Market Size Segment by Type

4.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue and Market Share by Type (2017-2022)

4.2 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5 Market Size Segment by Application

5.1 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Application (2017-2022)

5.2 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6 North America by Country, by Type, and by Application

6.1 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Type (2017-2028)

6.2 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Application (2017-2028)

6.3 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country

6.3.1 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Country (2017-2028)

6.3.2 United States Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Forecast (2017-2028)

6.3.3 Canada Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Forecast (2017-2028)

6.3.4 Mexico Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7 Europe by Country, by Type, and by Application

7.1 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Type (2017-2028)

7.2 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Application (2017-2028)

7.3 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country

7.3.1 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Country (2017-2028)

7.3.2 Germany Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Forecast (2017-2028)

7.3.3 France Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Forecast (2017-2028)

7.3.5 Russia Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Forecast (2017-2028)

7.3.6 Italy Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Type (2017-2028)

8.2 Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Application (2017-2028)

8.3 Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Region

8.3.1 Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Region (2017-2028)

8.3.2 China Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Forecast (2017-2028)

8.3.3 Japan Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Forecast (2017-2028)

8.3.4 South Korea Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Forecast (2017-2028)

8.3.5 India Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Forecast (2017-2028)

8.3.7 Australia Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9 South America by Country, by Type, and by Application

9.1 South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Type (2017-2028)

9.2 South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Application (2017-2028)

9.3 South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country

9.3.1 South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Country (2017-2028)

9.3.2 Brazil Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Forecast (2017-2028)

9.3.3 Argentina Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Type (2017-2028)

10.2 Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Application (2017-2028)

10.3 Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size by Country

10.3.1 Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Country (2017-2028)

10.3.2 Turkey Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Forecast (2017-2028)

10.3.4 UAE Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

11 Research Findings and Conclusion

12 Appendix

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue (USD Million) by Region (2017-2022)

Table 5. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Region (2023-2028)

Table 6. AbbVie Inc. Corporate Information, Head Office, and Major Competitors

Table 7. AbbVie Inc. Major Business

Table 8. AbbVie Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product and Solutions

Table 9. AbbVie Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Amgen Inc. Corporate Information, Head Office, and Major Competitors

Table 11. Amgen Inc. Major Business

Table 12. Amgen Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product and Solutions

Table 13. Amgen Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Johnson & Johnson Services, Inc. Corporate Information, Head Office, and Major Competitors

Table 15. Johnson & Johnson Services, Inc. Major Business

Table 16. Johnson & Johnson Services, Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product and Solutions

Table 17. Johnson & Johnson Services, Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. UCB S.A. Corporate Information, Head Office, and Major Competitors

Table 19. UCB S.A. Major Business

Table 20. UCB S.A. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product and Solutions

Table 21. UCB S.A. Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Novartis International AG Corporate Information, Head Office, and Major Competitors

Table 23. Novartis International AG Major Business

Table 24. Novartis International AG Tumor Necrosis Factor (TNF) Inhibitor Drugs Product and Solutions

Table 25. Novartis International AG Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Pfizer, Inc. Corporate Information, Head Office, and Major Competitors

Table 27. Pfizer, Inc. Major Business

Table 28. Pfizer, Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product and Solutions

Table 29. Pfizer, Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Merck & co., Inc. Corporate Information, Head Office, and Major Competitors

Table 31. Merck & co., Inc. Major Business

Table 32. Merck & co., Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Product and Solutions

Table 33. Merck & co., Inc. Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 35. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 36. Breakdown of Tumor Necrosis Factor (TNF) Inhibitor Drugs by Company Type (Tier 1, Tier 2 and Tier 3)

Table 37. Tumor Necrosis Factor (TNF) Inhibitor Drugs Players Head Office, Products and Services Provided

Table 38. Tumor Necrosis Factor (TNF) Inhibitor Drugs Mergers & Acquisitions in the Past Five Years

Table 39. Tumor Necrosis Factor (TNF) Inhibitor Drugs New Entrants and Expansion Plans

Table 40. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue (USD Million) by Type (2017-2022)

Table 41. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Share by Type (2017-2022)

Table 42. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Forecast by Type (2023-2028)

Table 43. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Application (2017-2022)

Table 44. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Forecast by Application (2023-2028)

Table 45. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Type (2017-2022) & (USD Million)

Table 46. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Type (2023-2028) & (USD Million)

Table 47. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Application (2017-2022) & (USD Million)

Table 48. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Application (2023-2028) & (USD Million)

Table 49. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Country (2017-2022) & (USD Million)

Table 50. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Country (2023-2028) & (USD Million)

Table 51. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Type (2017-2022) & (USD Million)

Table 52. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Type (2023-2028) & (USD Million)

Table 53. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Application (2017-2022) & (USD Million)

Table 54. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Application (2023-2028) & (USD Million)

Table 55. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Country (2017-2022) & (USD Million)

Table 56. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Country (2023-2028) & (USD Million)

Table 57. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Type (2017-2022) & (USD Million)

Table 58. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Type (2023-2028) & (USD Million)

Table 59. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Application (2017-2022) & (USD Million)

Table 60. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Application (2023-2028) & (USD Million)

Table 61. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Region (2017-2022) & (USD Million)

Table 62. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Region (2023-2028) & (USD Million)

Table 63. South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Type (2017-2022) & (USD Million)

Table 64. South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Type (2023-2028) & (USD Million)

Table 65. South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Application (2017-2022) & (USD Million)

Table 66. South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Application (2023-2028) & (USD Million)

Table 67. South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Country (2017-2022) & (USD Million)

Table 68. South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Country (2023-2028) & (USD Million)

Table 69. Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Type (2017-2022) & (USD Million)

Table 70. Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Type (2023-2028) & (USD Million)

Table 71. Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Application (2017-2022) & (USD Million)

Table 72. Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Application (2023-2028) & (USD Million)

Table 73. Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Country (2017-2022) & (USD Million)

Table 74. Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Tumor Necrosis Factor (TNF) Inhibitor Drugs Picture

Figure 2. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Type in 2021

Figure 3. Humira

Figure 4. Enbrel

Figure 5. Remicade

Figure 6. Simponi/Simponi Aria

Figure 7. Cimzia

Figure 8. Biosimilars

Figure 9. Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Application in 2021

Figure 10. Rheumatoid Arthritis Picture

Figure 11. Psoriasis Picture

Figure 12. Psoriatic Arthritis Picture

Figure 13. Crohn’s Disease Picture

Figure 14. Ulcerative Colitis Picture

Figure 15. Ankylosing Spondylitis Picture

Figure 16. Juvenile Idiopathic Arthritis Picture

Figure 17. Hidradenitis Suppurativa Picture

Figure 18. Others Picture

Figure 19. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 20. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue and Forecast (2017-2028) & (USD Million)

Figure 21. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Region (2017-2028)

Figure 22. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Region in 2021

Figure 23. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue (USD Million) and Growth Rate (2017-2028)

Figure 24. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue (USD Million) and Growth Rate (2017-2028)

Figure 25. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue (USD Million) and Growth Rate (2017-2028)

Figure 26. South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue (USD Million) and Growth Rate (2017-2028)

Figure 27. Middle East and Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue (USD Million) and Growth Rate (2017-2028)

Figure 28. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Drivers

Figure 29. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Restraints

Figure 30. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Trends

Figure 31. AbbVie Inc. Recent Developments and Future Plans

Figure 32. Amgen Inc. Recent Developments and Future Plans

Figure 33. Johnson & Johnson Services, Inc. Recent Developments and Future Plans

Figure 34. UCB S.A. Recent Developments and Future Plans

Figure 35. Novartis International AG Recent Developments and Future Plans

Figure 36. Pfizer, Inc. Recent Developments and Future Plans

Figure 37. Merck & co., Inc. Recent Developments and Future Plans

Figure 38. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Share by Players in 2021

Figure 39. Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 40. Global Top 3 Players Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share in 2021

Figure 41. Global Top 10 Players Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share in 2021

Figure 42. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 43. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Share by Type in 2021

Figure 44. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share Forecast by Type (2023-2028)

Figure 45. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Share by Application in 2021

Figure 46. Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Share Forecast by Application (2023-2028)

Figure 47. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share by Type (2017-2028)

Figure 48. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share by Application (2017-2028)

Figure 49. North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Country (2017-2028)

Figure 50. United States Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 51. Canada Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 52. Mexico Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 53. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share by Type (2017-2028)

Figure 54. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share by Application (2017-2028)

Figure 55. Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Country (2017-2028)

Figure 56. Germany Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 57. France Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 58. United Kingdom Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. Russia Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 60. Italy Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share by Type (2017-2028)

Figure 62. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share by Application (2017-2028)

Figure 63. Asia-Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Region (2017-2028)

Figure 64. China Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 65. Japan Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 66. South Korea Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 67. India Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. Southeast Asia Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. Australia Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 70. South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share by Type (2017-2028)

Figure 71. South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share by Application (2017-2028)

Figure 72. South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Country (2017-2028)

Figure 73. Brazil Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 74. Argentina Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. Middle East and Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share by Type (2017-2028)

Figure 76. Middle East and Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Sales Market Share by Application (2017-2028)

Figure 77. Middle East and Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue Market Share by Country (2017-2028)

Figure 78. Turkey Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 79. Saudi Arabia Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 80. UAE Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 81. Methodology

Figure 82. Research Process and Data Source